Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

AstraZeneca's asthma maintenance treatment receives US FDA approval

(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it asthma maintenance treatment Breztri Aerosphere had received approval from the US Food and Drug Administration for adults and adolescents aged 12 and over. AstraZeneca said the latest approval from the FDA was supported by data from its recent Phase III KALOS and LOGOS trials, which assessed Breztri in a broad asthma population, including patients with and without recent exacerbations.

In both studies, AstraZeneca said the therapy delivered "a statistically significant and clinically meaningful improvement" in lung function compared with dual‑combination ICS/LABA treatments.

The FTSE 100-listed firm also said Breztri showed a rapid onset of action, with a significant improvement in lung function seen within five minutes of the first dose.

AstraZeneca highlighted that its fixed‑dose triple‑combination single‑inhaler therapy was already approved in the US for chronic obstructive pulmonary disease and was prescribed to more than 6.8m patients globally in 2025.

Ruud Dobber, executive vice president of AstraZeneca's biopharmaceuticals business unit, said: "As the fastest growing fixed-dose triple-combination therapy in COPD, Breztri is already improving outcomes for people suffering with COPD, and we are proud to extend its benefits to asthma patients. The FDA's approval of Breztri in asthma demonstrates how our innovative science continues to bring new solutions for patients with respiratory diseases."

As of 0915 BST, AstraZeneca shares were down 1.53% at 13,758p.

Reporting by Iain Gilbert at Sharecast.com

See latest RNS at Investegate

Share this article

Related Sharecast Articles

Berenberg raises target price on Persimmon, keeps 'hold' rating
(Sharecast News) - Analysts at Berenberg raised their target price on housebuilder Persimmon from 1,150p to 1,240p on Friday after lifting their 2026-27 earnings per share estimates by an average of 2% following the group's third-quarter trading update.
Wise H1 profits climb as customer base tops 16m
(Sharecast News) - Global fintech group Wise reported a jump in first-half revenue and profits on Friday, putting the recently dual-listed firm on track to hit the upper end of its full-year growth targets.
GSK wins positive CHMP opinion for Bexsero meningitis B booster
(Sharecast News) - Pharmaceutical giant GSK said on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use had issued a positive opinion recommending a label update for its Bexsero meningitis B vaccine.
Major Microsoft outage hits hospitals, businesses and financial markets worldwide
(Sharecast News) - A global Microsoft outage has disrupted businesses, government agencies and other organisations worldwide, leaving users without a slew of vital services in what is one of the group's most prolonged service disruptions in history.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.